Skip to main content
Top
Published in: Familial Cancer 4/2011

01-12-2011

Factors affecting encouragement of relatives among families with Lynch syndrome to seek medical assessment

Authors: Noriko Ishii, Masami Arai, Yurie Koyama, Masashi Ueno, Toshiharu Yamaguchi, Keiko Kazuma, Tetsuichiro Muto

Published in: Familial Cancer | Issue 4/2011

Login to get access

Abstract

Lynch syndrome (HNPCC) is an autosomal dominant hereditary cancer syndrome, and members of affected families are at-risk for developing colorectal and other associated tumors. Such individuals should disseminate familial genetic information, so they can seek specific medical assessment or genetic testing to reduce mortality and morbidity rates by early detection. Since published results have been encouraging, we explored which factors influence the likelihood of good communication within families regarding medical assessment. We studied 40 individuals from 33 families who satisfied the Japanese clinical criteria for Lynch syndrome and their relatives at our hospital. We determined the status of relatives of the 40 individuals after genetic counseling and testing using questionnaires and semi-structured interviews based on pedigree charts. We also examined their knowledge or perception of colorectal cancer syndrome, levels of intimacy and whether or not they encouraged their relatives to have specific medical assessments. We found that 75% of the individuals advised their relatives to seek medical assessment, and any significant background factors that promoted such encouragement were observed. They tended to encourage first degree relatives and discuss the issue with other family members such as spouses before undertaking such attempts at encouragement. The reasons and methods of imparting encouragement were essentially identical. We also found that genetic testing for at-risk or more distant relatives was not encouraged so often. Therefore, providing individuals who have been tested for Lynch syndrome with opportunities for disseminating familial genetic information through appropriate genetic counseling is important.
Literature
1.
go back to reference Review of Ethical Issues in Medical Genetics (WHO/HGN/ETH/2000.4) Review of Ethical Issues in Medical Genetics (WHO/HGN/ETH/2000.4)
2.
go back to reference Council on Ethical and Judicial Affairs of the American Medical Association. Opinion E-2, 131: Disclosure of Familial Risk in Genetic Testing. American Medical Association, Code of Medical Ethics: Current Opinion Council on Ethical and Judicial Affairs of the American Medical Association. Opinion E-2, 131: Disclosure of Familial Risk in Genetic Testing. American Medical Association, Code of Medical Ethics: Current Opinion
3.
go back to reference American Society of Clinical Oncology (2003) Policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21:2397–2406CrossRef American Society of Clinical Oncology (2003) Policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21:2397–2406CrossRef
4.
go back to reference Pentz RD, Peterson SK, Watts BG, Vernon SW, Lynch PM, Koehly LM, Gritz ER (2005) Hereditary nonpolyposis colorectal cancer family members’ perceptions about the duty to inform and health professionals’ role in disseminating genetic information. Genet Test Fall 9(3):261–268CrossRef Pentz RD, Peterson SK, Watts BG, Vernon SW, Lynch PM, Koehly LM, Gritz ER (2005) Hereditary nonpolyposis colorectal cancer family members’ perceptions about the duty to inform and health professionals’ role in disseminating genetic information. Genet Test Fall 9(3):261–268CrossRef
5.
go back to reference Murakami Y, Okamura H, Sugano K, Toshida T, Kazuma K, Akechi T, Uchitomi Y (2004) Psychologic distress after disclosure of genetic test results regarding hereditary nonpolyposis colorectal carcinoma, a preliminary report. Cancer 101(2):395–403PubMedCrossRef Murakami Y, Okamura H, Sugano K, Toshida T, Kazuma K, Akechi T, Uchitomi Y (2004) Psychologic distress after disclosure of genetic test results regarding hereditary nonpolyposis colorectal carcinoma, a preliminary report. Cancer 101(2):395–403PubMedCrossRef
6.
go back to reference Halbert CH, Lynch H, Lynch J, Main D, Kucharski S, Rustgi AK, Lerman C (2004) Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch Intern Med 104(17):1661–1667 Halbert CH, Lynch H, Lynch J, Main D, Kucharski S, Rustgi AK, Lerman C (2004) Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch Intern Med 104(17):1661–1667
7.
go back to reference Keller M, Just R, Haunstetter CM, Sattel H, Schroeter C, Cremer F, Kienle P, Tariverdian M, Kloor M, Gebert J, Brechtel A (2008) Psychosocial outcome following genetic risk counselling for familial colorectal cancer. A comparison of affected patients and family members. Clin Genet 74(5):414–424PubMedCrossRef Keller M, Just R, Haunstetter CM, Sattel H, Schroeter C, Cremer F, Kienle P, Tariverdian M, Kloor M, Gebert J, Brechtel A (2008) Psychosocial outcome following genetic risk counselling for familial colorectal cancer. A comparison of affected patients and family members. Clin Genet 74(5):414–424PubMedCrossRef
8.
go back to reference Carlsson C, Nilbert M (2007) Living with hereditary non-polyposis colorectal cancer; experiences from and impact of genetic testing. J Genet Couns 16(6):811–820PubMedCrossRef Carlsson C, Nilbert M (2007) Living with hereditary non-polyposis colorectal cancer; experiences from and impact of genetic testing. J Genet Couns 16(6):811–820PubMedCrossRef
9.
go back to reference Peterson SK, Watts BG, Koehly LM, Vernon SW, Baile WF, Kohlmann WK, Gritz ER (2003) How families communicate about HNPCC genetic testing: findings from a qualitative study. Am J Med Genet C Semin Med Genet 119(1):78–86CrossRef Peterson SK, Watts BG, Koehly LM, Vernon SW, Baile WF, Kohlmann WK, Gritz ER (2003) How families communicate about HNPCC genetic testing: findings from a qualitative study. Am J Med Genet C Semin Med Genet 119(1):78–86CrossRef
10.
go back to reference Mesters I, Ausems M, Eichhorn S, Vasen H (2005) Informing one’s family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer 4(2):163–167PubMedCrossRef Mesters I, Ausems M, Eichhorn S, Vasen H (2005) Informing one’s family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer 4(2):163–167PubMedCrossRef
11.
go back to reference Koehly LM, Peterson SK, Watts BG, Kempi KK, Vernon SW, Gritz ER (2003) A social network analysis of communication about hereditary nonpolyposis colorectal cancer genetic testing and family functioning. Cancer Epidemiol Biomarkers Prev 12(4):304–313PubMed Koehly LM, Peterson SK, Watts BG, Kempi KK, Vernon SW, Gritz ER (2003) A social network analysis of communication about hereditary nonpolyposis colorectal cancer genetic testing and family functioning. Cancer Epidemiol Biomarkers Prev 12(4):304–313PubMed
12.
go back to reference Wagner A, van Kessei I, Kriege MG, Tops CM, Wijnen HF, van der Meer CA, van Oostrom II, Meijers-Heijboer H (2005) Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. Fam Cancer 4(4):295–300PubMedCrossRef Wagner A, van Kessei I, Kriege MG, Tops CM, Wijnen HF, van der Meer CA, van Oostrom II, Meijers-Heijboer H (2005) Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. Fam Cancer 4(4):295–300PubMedCrossRef
13.
go back to reference Gritz ER, Peterson SK, Vernon SW, Marani SK, Baile WF, Watts BG, Amos CI, Frazier ML, Lynch PM (2005) Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 23(3):1902–1910PubMedCrossRef Gritz ER, Peterson SK, Vernon SW, Marani SK, Baile WF, Watts BG, Amos CI, Frazier ML, Lynch PM (2005) Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 23(3):1902–1910PubMedCrossRef
14.
go back to reference Hadley DW, Jenkins J, Diamond E, Nakahara K, Grogan L, Liewehr DJ, Steinberg SM, Kirsch I (2003) Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch intern Med 103(5):573–582CrossRef Hadley DW, Jenkins J, Diamond E, Nakahara K, Grogan L, Liewehr DJ, Steinberg SM, Kirsch I (2003) Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch intern Med 103(5):573–582CrossRef
15.
go back to reference Gaff CL, Collins V, Symes T, Halliday J (2005) Facilitating family communication about predictive genetic testing: probands’ perceptions. J Genet Couns 14(2):133–140PubMedCrossRef Gaff CL, Collins V, Symes T, Halliday J (2005) Facilitating family communication about predictive genetic testing: probands’ perceptions. J Genet Couns 14(2):133–140PubMedCrossRef
16.
go back to reference Erna C, Gerry EK, Andrea B, Marleen D, Lieve D, Eric L (2002) Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer patients. Am J Med Genet 116A:11–19 Erna C, Gerry EK, Andrea B, Marleen D, Lieve D, Eric L (2002) Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer patients. Am J Med Genet 116A:11–19
Metadata
Title
Factors affecting encouragement of relatives among families with Lynch syndrome to seek medical assessment
Authors
Noriko Ishii
Masami Arai
Yurie Koyama
Masashi Ueno
Toshiharu Yamaguchi
Keiko Kazuma
Tetsuichiro Muto
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2011
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9462-x

Other articles of this Issue 4/2011

Familial Cancer 4/2011 Go to the issue

Abstract

Abstracts

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine